TNFRSF1A and metabolic dysfunction-associated steatotic liver disease: Treatment of NAFLD mice with anti-TNFR1 significantly reduced liver steatosis as compared to control-Ab treatment (52.9 ± 9.4% vs. 76.7 ± 3.3%, p < 0.05; Fig. 1a, b).